CASTLEMAN DISEASE: A GREAT MIMICKER OF METASTASES IN RADIOIODINE REFRACTORY THYROID CANCER
A 27-year-old male underwent total thyroidectomy for thyroid swelling. Histopathology showed papillary thyroid carcinoma [T3 - 6.0 cm] with extra-thyroidal extension. The patient was treated with 150 mCi radioactive iodine
(RAI) as adjuvant ablative therapy. Radioiodine refractory disease was identified 1-year post-RAI therapy with elevated thyroglobulin levels and negative I-131 whole body scan. F-18 FDG positron emission tomography/computed
tomography scan showed activity in the right thyroid bed and multilevel right cervical nodes. Right-sided modified neck dissection was done, which showed Castleman disease (hyaline vascular type) in right cervical nodes. The most probable cause of elevated tumour markers was found out to be 0.6 cm right thyroid bed nodule on follow-up ultrasonography. Our patient also had coexistent conditions as; osteopoikilosis and Hepatitis C along with thyroid carcinoma.
Key words: Castleman disease, lymph node, radioiodine, thyroid cancer
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30.
Bonekamp D, Horton KM, Hruban RH, et al. Castleman disease: The great mimic. Radiographics 2011;31:1793-807.
Zeng YH, Chen CK, Lee CC. Castleman disease mimicking nodal recurrence of thyroid cancer. Endocrine 2016;51:384-6.
Lee HJ, Jeon HJ, Park SG, et al. Castleman’s disease of the spleen. World J Gastroenterol 2015;21:1675-9.
Talukder DY, Delpachitra SN. Multicentric castleman’s disease in a hepatitis C-positive intravenous drug user: A case report. Case Rep Med 2011;2011:567840.
Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of castleman disease. Cancer Control 2014;21:266-78.
Nagubandi R, Wang Y, Dutcher JP, et al. Classic case of unicentric mixed-type castleman’s disease. J Clin Oncol 2013;31:e452-5.
Ferry J, Harris N. Atlas of Lymphoid Hyperplasia and Lymphoma. Philadelphia, PA: WB Saunders; 1997.
Amine C, Abdelatif O, Nouredine E. A rare case of castleman’s disease presenting as cervical neck mass. Internet J Otorhinolaryngol 2008;9:1-4.
Talat N, Belgaumkar AP, Schulte KM. Surgery in castleman’s disease: A systematic review of 404 published cases. Ann Surg 2012;255:677-84.
Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of castleman’s disease. Am J Hematol 2012;87:997-1002.
Dispenzieri A, Gertz MA. Treatment of castleman’s disease.
Curr Treat Options Oncol 2005;6:255-66.
Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric castleman’s disease: A report of 16 cases and a review of the literature. Cancer 1999;85:706-17.
Gild ML, Topliss DJ, Learoyd D, et al. Clinical guidance for radioiodine refractory differentiated thyroid cancer. Clin Endocrinol (Oxf) 2018;88:529-37.
Sfar R, Kamoun T, Nouira M, et al. Differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS syndrome). Int J Otolaryngol 2014;3:149-53.
Özdemir E, Yildirim Poyraz N, Polat SB, et al. Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: Correlation with thyroglobulin levels. Ann Nucl Med 2014;28:241-7.
Negi RS, Manchanda KL, Sanga S, et al. Osteopoikilosisspotted bone disease. Med J Armed Forces India 2013;69:196-8.
Tsai SY, Wang SY, Shiau YC, et al. Benign incidental findings of osteopoikilosis on tc-99m MDP bone SPECT/ CT: A case report and literature review. Medicine (Baltimore) 2016;95:e3868.
Korkmaz MF, Elli M, Özkan MB, et al. Osteopoikilosis: Report of a familial case and review of the literature. Rheumatol Int 2015;35:921-4.
Woyciechowsky TG, Monticielo MR, Keiserman B, et al. Osteopoikilosis: What does the rheumatologist must know about it? Clin Rheumatol 2012;31:745-8.
Di Primio G. Benign spotted bones: A diagnostic dilemma. CMAJ 2011;183:456-9.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.